Last reviewed · How we verify
ALZ-101
At a glance
| Generic name | ALZ-101 |
|---|---|
| Sponsor | Alzinova AB |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Extension Study of Participants From SPG302-ALZ-101 (PHASE2)
- A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALZ-101 CI brief — competitive landscape report
- ALZ-101 updates RSS · CI watch RSS
- Alzinova AB portfolio CI